Age, mean ± SD, years |
68 ± 8 |
69 ± 7.8 |
64 ± 15.6 |
67 ±
6 |
Male Gender |
50% (9/18) |
37.5% (3/8) |
100% (2/2) |
0
(0/3) |
African American race |
16.7% (3/18) |
12.5% (1/8) |
50% (1/2) |
33.3% (1/3) |
Immunosuppression |
33.3% (6/18) |
37.5% (3/8) |
50% (1/2) |
33.3%
(1/3) |
Body mass index |
33.8 ± 12.3 |
28.9 ± 4.8 |
33.6 ± 16.5 |
44.6 ±
24.6 |
Diabetes mellitus |
77.8% (14/18) |
75% (6/8) |
50% (1/2) |
100%
(3/3) |
Days of intubation prior to BAL |
3.6 ± 3.6 |
3.6 ± 2.1 |
4 ± 4.2 |
1.7
± 1.1 |
Days from symptoms to BAL, days |
13.6 ± 7.8 |
14.8 ± 7.6 |
12 ± 4.2 |
14 ±7 |
Dexamethasone prior to BAL |
100% |
100% |
100% |
100% |
Tocilizumab prior to BAL |
0 |
0 |
50% (1/1) |
0 |
Remdesivir prior to BAL |
55.6% (10/18) |
62.5% (5/8) |
50% (1/1) |
33% (1/3) |
Max temperature*, mean ± SD, 0C |
37.7 ±1.1 |
37.7
±0.8 |
37.8 ±1.7 |
37.9 ±1.9 |
Vasopressors* |
72.2% (13/18) |
75% (6/8) |
100% (2/2) |
33%
(1/3) |
Min PaO2/FiO2* |
161.4 ± 93.2 |
153.8 ± 121.1 |
102.5 ± 20.6 |
200.5 ±
110.5 |
CRP*, mean ±SD, mg/L |
155.2 ± 117.1 |
105.6 ± 79 |
147.9 ± 81.7 |
151.3
± 50.8 |
Max WBC*, mean ± SD, cells/µL |
13.3 ± 6.3 |
12.5 ± 5.8 |
12.8 ±4.1 |
12.7 ± 6.1 |
Min lymphocyte count*, mean ± SD cells/µL |
0.7 ± 0.4 |
0.6 ± 0.3 |
0.9
± 1.1 |
0.5 ± 0.1 |
BAL neutrophil % |
38.5 ± 29.8 |
22.8 ± 23.7 |
43 ± 41 |
38 |
BAL lymphocyte % |
8.4 ± 8.7 |
9.2 ± 7.7 |
3.5 ± 2.1 |
28 |
Ct value, mean ± SD |
22 ± 6.5 |
26.6 ± 2.6 |
20 ± 1.1 |
14.4 ±
1.2 |
Ventilator- free days, mean ±SD, days |
1.8 ± 2.9 |
1.6 ± 3.1 |
1.5 ±
2.1 |
1.3 ± 2.3 |
Length of stay, mean ± SD, days |
31.1 ± 15.6 |
28 ± 11.4 |
51.5 ± 3.5 |
18.7 ± 14.4 |
Mortality |
66.7% (12/18) |
75% (6/8) |
50% (1/2) |
100%
(3/3) |